drugset / Trial / NCT04405622
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.
Timeline
- Start
- 2020-05-30
- Primary completion
- 2023-03
- Completion
- 2023-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |